Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Hetero ring containing

Subclass of:

514 - Drug, bio-affecting and body treating compositions

514001000 - DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI)

514169000 - Cyclopentanohydrophenanthrene ring system DOAI

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
514174000 -O-C-O- is part of a hetero ring (e.g., acetonide, etc.) 64
514176000 Nitrogen containing hetero ring 57
514173000 Spiro ring system 38
514175000 -C(=O)-O-is part of a hetero ring (e.g., lactone, etc.) 15
Entries
DocumentTitleDate
20090221542Inhibition of Inflammatory Cytokine Production With Tanshinones - Provided are methods of attenuating release of a proinflammatory cytokine from a mammalian cell. Also provided are methods of inhibiting or treating an inflammatory cytokine cascade in a mammal. Further provided are methods of treating a mammal at risk for or undergoing sepsis, septicemia, and/or endotoxic shock. Additionally provided are methods of attenuating NO release from a mammalian cell. Also provided are methods of attenuating NO production in a mammal at risk for, or having, a disorder mediated by excessive NO production.09-03-2009
20100075936USE OF GLUCOCORTICOID RECEPTOR ANTAGONISTS FOR TREATMENT OF INFECTIOUS CONDITIONS - The invention provides the use of a glucocorticoid receptor antagonist for the manufacture of a medicament for immune stimulation, such as prevention or treatment of infections or infectious conditions, in an aging mammalian subject, a mammalian subject with low serum DHEAS values, a mammalian subject with a high serum cortisol/DHEAS ratio or a mammalian subject with high neutrophil counts. In particular, the glucocorticoid receptor antagonist can be chosen from the group consisting of a dibenzopyranyl derivative defined and/or exemplified in U.S. Pat. No. 6,329,534 and WO200116128, mifepristone, and (11β,17β)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one.03-25-2010
20090239834MCC-257 MODULATION OF NEUROGENESIS - The disclosure provides methods and a composition for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis by use of (5-acetamido-N-(5alpha-cholestan-3alpha-yl)-3,5-dideoxy-2-O-methyl-D-glycero-alpha-D-galacto-non-2-ulopyranosonamide(MCC-257). The disclosure also includes methods and a composition for stimulating or activating the formation of new nerve cells based on the application of MCC-25709-24-2009
20090325917Pharmaceutical Compositions and Nasal Spray Incorporating Anhydrous Mometasone Furoate - A stable aqueous pharmaceutical composition comprising anhydrous mometasone furoate and a pharmaceutically acceptable carrier.12-31-2009
20100331290TAXANE DELIVERY SYSTEM - Nanoparticulate formulations for delivery of taxane conjugate prodrug formed from a taxane coupled to a hydrophobic moiety through a glycolate linker are described.12-30-2010
20100029602LOW-DOSE MOMETASONE FORMULATIONS - Provided is a topical cream composition for the delivery of mometasone furoate comprising low dose mometasone furoate for the treatment of corticosteroid responsive dermatoses. The composition of the present invention can be safely applied over large surface areas of the skin (including areas with wrinkles and/or hair), and can be used therapeutically for extended periods of time (e.g., greater than 3 weeks). Treatment with the composition of the present invention carries reduced and/or fewer side effects compared with commercially available mometasone furoate cream products. The cream composition of the present invention is safe for the use of babies and infants under 2 years old. Additionally provided are methods of preparing and using the composition of the invention.02-04-2010
20120065178OCULAR THERAPY USING GLUCOCORTICOID DERIVATIVES SELECTIVELY PENETRATING POSTERIOR SEGMENT TISSUES - Ophthalmically therapeutic materials, such as liquid-containing compositions and polymeric drug delivery systems, include a therapeutic component that includes an Glucocorticoid Derivative which, upon delivery to the posterior segment of a mammalian eye, does not significantly diffuse to the anterior segment of said eye. Methods of making and using the present materials are also described.03-15-2012
20090082318DEUTERIUM-ENRICHED MOMETASONE - The present application describes deuterium-enriched mometasone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.03-26-2009
20090143347Use of 3-methoxy-pregnenolone for the preparation of a drug for treating depressive disorders and long-term neurological diseases - The invention relates to the therapeutic use of pregnenolone derivatives for treating depressive disorders and long-term neurological diseases.06-04-2009
20100279992USE OF LANOSTANE AND PORIA EXTRACT IN TREATING CACHEXIA - A pharmaceutical composition for treating cachexia, and in particular for treating cancer cachexia. The composition contains a lanostane compound as a potent component. A suitable source of the lanostane compound is a 11-04-2010
20080242651SOFT ANTICHOLINERGIC ZWITTERIONS - Soft anticholinergic zwitterions of the formulas:10-02-2008
20090156567NOVEL ANTI-INFLAMMATORY ANDROSTANE DERIVATIVE - According to one aspect of the invention, there is provided a compound of formula (I)06-18-2009
20090143346Method for synthesizing furanosteroids - The present invention is a method for synthesizing furanosteroids. The method involves intramolecular Diels-Alder/retro-Diels-Alder reaction and tautomerization of a functionalized alkyne oxazole to produce a furo[2,3-b]phenol derivative which is elaborated by intermolecular and intramolecular condensations to generate ring-A of the furanosteroid. Furanosteroids and pharmaceutical compositions containing the same are also provided.06-04-2009
20120142651METHOD OF TREATMENT OF ALLERGIC RHINITIS - There is provided a method of treatment of allergic rhinitis which comprises administering to a patient a pharmaceutically acceptable amount of a pharmaceutical formulation comprising an aqueous suspension of particulate compound of formula (I)06-07-2012
20090209504Use of Digitalis-Like Compounds in the Treatment of Affective Disorders - Use of digitalis-like compounds such as 19-norbufalin derivatives in the treatment of affective disorders such as anxiety, depression and bipolar disorders is disclosed.08-20-2009
201301232234-PREGENEN-11BETA-17-21-TRIOL-3,20-DIONE DERIVATIVES - The present invention relates to novel 4-pregenen-11β-17-21-triol-3,20-dione derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals, as modulators of glucocorticoid or mineralocorticoid receptors. The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat disorders associated with glucocorticoid or mineralocorticoid receptor modulation.05-16-2013
20120196841Ceramide Production Enhancer and Moisturizer - A ceramide production enhancer and a moisturizer containing, as an active ingredient, an extract of at least one plant selected from the group consisting of 08-02-2012
20100240629POLYMORPHS OF FLUTICASONE FUROATE AND PROCESSES FOR PREPARATION THEREOF - The present invention provides crystalline forms of Fluticasone furoate, characterized by the data disclosed in the specification; pharmaceutical compositions comprising any one or combination of the crystalline forms of Fluticasone furoate and at least one pharmaceutically acceptable excipient; and the use of the crystalline forms of Fluticasone furoate in the preparation of pharmaceutical formulations.09-23-2010
20100144689COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS - As described herein, the present invention provides compounds useful for treating or lessening the severity of a neurodegenerative disorder. The present invention also provides methods of treating or lessening the severity of such disorders wherein said method comprises administering to a patient a compound of the present invention, or composition thereof. Said method is useful for treating or lessening the severity of, for example, Alzheimer's disease.06-10-2010
20100210612DETECTION OF ESR1 AMPLIFICATION IN ENDOMETRIUM CANCER AND OVARY CANCER - The present invention relates to an in-vitro method of identifying a tumor resulting from a proliferative disease of the endometrium or ovary as responsive to anti-estrogen treatment. Further, the invention relates to an in-vitro method of identifying a candidate patient with a proliferative disease of the endometrium or ovary as suitable for anti-estrogen treatment. In a further aspect, the invention provides an in-vitro method of identifying an individual with a non-cancerous proliferative disease of the endometrium or ovary who is at risk of developing endometrial or ovarian cancer. The invention also provides kits for performing the above methods.08-19-2010
20090111786Compounds that Prevent Macrophage Apoptosis and Uses Thereof - The present invention relates to microbial infection, and in particular, the reduction of apoptosis associated with microbial infection, the screening of Liver X Receptor agonist and/or Retinoid X Receptor agonist that reduce apoptosis, and the treatment and analysis of microbial infection in vivo. In one embodiment, the present invention relates to Liver X Receptor agonist and/or Retinoid X Receptor agonist including but not limited to an agonist increasing the activity of Liver X Receptor and/or Retinoid X Receptor.04-30-2009
20090124585Novel Crystalline Pharmaceutical Product - There are provided crystalline particles of unsolvated Form 1 polymorph of the compound of formula (I):05-14-2009
20100016267Pharmaceutical compositions for administraton to a sinus - Pharmaceutical compositions for delivering a drug to a sinus in a subject are provided. The compositions are formed by the combination of a carrier material and a drug and are specially adapted for delivery to a sinus. The compositions have no fixed shape, and the carrier material serves to increase the viscosity or specific volume of the composition after introduction of the composition into the sinus. Also provided are methods for delivering a drug to a subject. The methods entail administering a pharmaceutical composition according to the present invention directly to a sinus. The drug is then released from the composition to the sinus. The pharmaceutical compositions can be administered to a sinus in liquid form, for example, as a suspension or solution using standard techniques. Also provided is the use of a carrier material in the manufacture of a drug delivery composition. The drug delivery composition is for delivering a drug to a sinus in a subject. The composition comprises the carrier material combined with the drug to be delivered, and has no fixed shape. After the composition is introduced into a sinus, the carrier material serves to increase the viscosity or specific volume of the composition.01-21-2010
20100298280Compounds for the Modulation of Huntingtin Aggregation, Methods and Means for Identifying Such Compounds - The present invention relates to tetranortriterpenoid compounds and pharmaceutical compositions thereof, which are provided for use in the treatment, diagnosis and/or prevention of trinucleotide repeat disorders (like a polyglutamine diseases, e.g Huntingdon's disease), amyloid diseases, neurodegenerative disease, protein misfolding diseases or tumors. The tetranortriterpenoid compounds of the present invention are further provided for the reduction and/or inhibition of the aggregation of amyloidogenic proteins, preferably of polyglutamine proteins (such as huntingtin) as well as for increasing proteasome activity. The present invention furthermore relates to nucleic acids, comprising the nucleotide sequences of two huntingtin fragments, as well as to cells and kits, which are useful in methods for assessing the aggregation of huntingtin and in methods for identifying compounds, which modulate the aggregation of huntingtin.11-25-2010
20120309728NEW STEROID INHIBITORS OF PGP FOR USE FOR INHIBITING MULTIDRUG RESISTANCE - The present invention relates to a compound of formula (I) for its use for reversing or inhibiting multidrug resistance.12-06-2012
20100179115USE OF A GLUCOCORTICOID RECEPTOR II ANTAGONIST TO TREAT DEPRESSION IN PATIENTS TAKING IL-2 - The invention pertains to the discovery that type II glucocorticoid receptor antagonists can be used in methods for reversing or inhibiting the symptoms of depression in patients receiving interleukin-2 treatment.07-15-2010
2010014468823-Substituted Derivatives of Lupane-type Pentacyclic Triterpenoids - The present invention comprises small molecule inhibitors of cell proliferative conditions, in particular cancer and conditions associated with cancer. For example, associated malignancies include ovarian cancer, cervical cancer, breast cancer, colorectal cancer, and glioblastomas, among others. Accordingly, the compounds of the present invention are useful for treating, preventing, and/or inhibiting these diseases. Thus, the present invention also comprises pharmaceutical formulations comprising the compounds and methods of using the compounds and formulations to inhibit cancer and treat, prevent, or inhibit the foregoing diseases.06-10-2010
20120040944 MEDICINAL CREAM MADE USING MOMETASONE FUROATE AND CHITOSAN AND A PROCESS TO MAKE THE SAME - The present invention relates to a composition for treating skin inflammation, along with skin rejuvenation. More particularly, the present invention relates to a pharmaceutical cream comprising a biopolymer, and a corticosteroid. It discloses a composition for treating skin inflammation, along with skin rejuvenation containing a) a biopolymer in the form of chitosan, b) an active pharmaceutical ingredient (API) composition in the form of mometasone furoate, used in treating skin inflammation c) a cream base containing primary and secondary emulsifiers, waxy materials, co-solvents, acids, preservatives, buffering agents, anti oxidants, chelating agents, and humectants and d) water. The active ingredients, namely chitosan, and a corticosteroid in the form of mometasone furoate, are incorporated in cream base for use in treating skin inflammation due to allergy & itching & wounds on human skin involving contacting human skin with the above identified composition.02-16-2012
20100130458Polymorphs of fluticasone furoate and process for preparation thereof - Provided are polymorphs of fluticasone furoate and processes for preparation thereof.05-27-2010
20120022032CORTICOSTEROID COMPOSITIONS AND METHODS OF TREATMENTS THEREOF - This invention relates to steroidal solutions for the preparation of medicaments and drug products useful for treating diseases of the upper and lower airway passages. Various embodiments of the present invention provide compositions, compositions and dosage forms with mometasone furoate in a dissolved state that are suitable for inhalation and can be used for the treatment of diseases of the upper and/or lower airway passages.01-26-2012
20120065177PHARMACEUTICAL FORMULATIONS COMPRISING AZELASTINE AND A CORTICOSTEROID FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS - The present invention relates to method for the treatment of allergic rhinitis comprising: administrating to a patient in need thereof a pharmaceutical formulation comprising a compound for formula (I)03-15-2012
20120108558Treatment of Hot Flashes - 16α,17α-Epoxy-10β-hydroxyestr-4-en-3-one is useful in the treatment of hot flashes by vomeronasal administration.05-03-2012
20100022493USE OF MOMETASONE FUROATE FOR TREATING AIRWAY PASSAGE AND LUNG DISEASE - The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and/or lower airway passages and/or lungs, e.g., allergic rhinitis and asthma is disclosed.01-28-2010
20110224180NOVEL CHOLEST-4-EN-3-ONE OXIME DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND PREPARATION METHOD - The present invention relates to novel chemical compounds, in particular cholest-4-en-3-one oxime derivatives and to the use thereof as medicaments, especially as cytoprotective medicaments, in particular neuroprotective, cardioprotective and/or hepatoprotective medicaments.09-15-2011
20100234334NITRIC OXIDE RELEASING STEROIDS - The invention relates to nitrooxyderivative of corticosteriods of general formula (I) and pharmaceutical acceptable salts or stereoisomers thereof wherein R is the corticosteriod residue of formulas (II): The compounds are useful in the treatment of respiratory diseases, inflammatory diseases, dermatological disease and ocular diseases.09-16-2010
20080300228Crystalline Rostafuroxin - New crystalline forms of 17β-(3-Furyl)-5-βandrostane-3β,14β,17α-triol are described together with pharmaceutical composition containing the same and methods for their preparation. In particular new Forms B, C, D, E and H are here described.12-04-2008
20110319372METHOD OF DIAGNOSING AND THERAPEUTICALLY TREATING A PATIENT FOR A TRAUMATIC BRAIN INJURY - Known or suspected traumatic brain injuries may be treated therapeutically by administering a therapeutically effective dose of resibufogenin. A preferred method for determining if a patient has a traumatic brain injury includes obtaining a body specimen from the patient, determining the concentration of marinobufagenin in the body specimen, comparing the concentration of marinobufagenin to the concentration in such body specimens in normal patients, and if the marinobufagenin concentration is substantially above the concentration of a normal patient, concluding traumatic brain injury exists. In a preferred embodiment, a substantial elevation is deemed to be an increase of about 30 percent above the marinobufagenin concentration of a normal patient. The body specimen may be blood, urine, or cerebrospinal fluid. If a substantial elevation is deemed to exist, the magnitude of the departure from the concentration of a normal patient may be employed in determining the timing and nature of treatment provided to the patient. The method may be repeated at predetermined intervals to monitor changes in the marinobufagenin with time.12-29-2011
20120101077AGGLOMERATE FORMULATIONS USEFUL IN DRY POWDER INHALERS - Several embodiments of the present invention provide for an agglomerate useful for an agglomerate based dry powder inhaler comprising at least one active pharmaceutical agent, at least one additional functional excipient and at least one excipient, such as a binder. Useful at least one additional functional excipients include but are not limited to magnesium stearate, colloidal silica, silicon dioxide, sucrose stearate, L-leucine and combinations thereof.04-26-2012
20130018024METHODS AND SYSTEMS FOR PHARMACOGENOMIC TREATMENT OF CARDIOVASCULAR CONDITIONS - Methods and systems are provided herein that are based on the effects of genetic variations on the biological activities associated to rostafuroxin in an individual. In particular, compositions, methods and systems are herein described that are based on an indentified influence on an individual response to rostafuroxin of one or more polymorphisms in an intergenic or intragenic region of a gene selected from the group consisting of KCNS3, THSD7A, FAM46A, LOC389970, HLA-G, and TTC29, and/or a genetic variation in linkage disequilibrium therewith.01-17-2013
20080249075C11 Modified Retrosteroids as Progesterone Receptor Modulator Compounds - Retrosteroidal compounds corresponding to formula I, representing progesterone receptor modulators, and their production, and pharmaceutical preparations containing these compounds. These compounds are useful in the treatment of benign gynecological disorders such as endometriosis and uterine fibroids, as well as for female birth control and for hormone replacement therapy.10-09-2008
20080234241MELANOGENESIS INHIBITORS AND WHITENING AGENTS COMPRISING ERGOSTEROL DERIVATIVE AND COMPOSITIONS CONTAINING ERGOSTEROL DERIVATIVE - It is intended to provide a substance which is efficacious in whitening sun-burnt skin after UV irradiation and preventing, ameliorating and treating skin pigmentation (for example, spots and freckles caused by sunburn, liver spots) and compositions containing the same. Melanogenesis inhibitors and whitening agents comprising an ergosterol derivative represented by formula (1); melanogenesis inhibitors and whitening agents containing the ergosterol derivative represented by the formula (1); melanogenesis inhibitory compositions and whitening compositions containing the ergosterol derivative represented by formula (1); cosmetics, drugs and external skin preparations containing the ergosterol derivative represented by formula (1); and melanogenesis inhibitory foods and whitening foods containing the ergosterol derivative represented by formula (1).09-25-2008
20080207574WITHANOLIDES, PROBES AND BINDING TARGETS AND METHODS OF USE THEREOF - Novel withanolide chemical genetic probes identify the in vivo binding target of withaferin A, which is the intermediate filament type III protein vimentin. In addition, a withanolide-based small molecule screening method screens drug candidates that target intermediate filament type III proteins. The method includes introducing a tagged linker covalently bonded to the withanolide molecule to form a withanolide probe. Better or alternative small molecule compounds as potential drug candidates can be generated based on their likely affinity for the determined binding site in vimentin. The affinity labeled withanolide can also be used to find intermediate filament-associated proteins using chemical proteomics by extracting proteins from cells that were exposed to withanolide-biotin analog. The withanolide probes can be used to monitor expression of vimentin, in tumor samples or other diseased tissues. Withaferin analogs can be used as a treatment for diverse vimentin-associated disorders, such as cancers, angiofibrotic diseases, and chronic inflammation.08-28-2008
20100292197Compositions and Methods for Increasing Telomerase Activity - The present invention relates to methods and compositions for increasing telomerase activity in cells. Such compositions include pharmaceutical formulations. The methods and compositions are useful for treating diseases subject to treatment by an increase in telomerase activity in cells or tissue of a patient. They are also useful for enhancing replicative capacity of cells in culture, as in ex vivo cell therapy and for enhancing proliferation of stem and progenitor cells.11-18-2010
20100317637ANTI-HEPATITIS C COMPOSITION AND METHOD FOR PREPARING DRUG FOR INHIBITING HEPATITIS C VIRUSES OR TREATING HEPATITIS C - The invention provides an anti-hepatitis C composition including: an effective amount of limonoid compound, wherein the structure of the limonoid compound is shown as Structure (I):12-16-2010
20130184244PROCESS FOR PREPARING DELTA-7,9(11) STEROIDS FROM GANODERMA LUCIDUM AND ANALOGS THEREOF - Processes for preparing lanostane triterpenes from the medicinal mushroom 07-18-2013
20130203717Process for Particle Processing of Active Pharmaceutical Ingredients - A process for reducing the particle size of an active pharmaceutical ingredient (API) while maintaining its polymorphic form, comprises the step of processing the active pharmaceutical ingredient by cavitation at elevated pressure. The process preferably comprises the step of isolating the processed active ingredient in the form of powder, wherein the isolation step comprises filtration or spray drying. Particles produced by the process of the invention typically have a span value of less than 2.5.08-08-2013

Patent applications in class Hetero ring containing

Patent applications in all subclasses Hetero ring containing